Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: Evidence for difference in the structure- function relationship

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 744-750

  Nicole, Pascal ^a   Du, Kai ^a   Couvineau, Alain ^a   Laburthe, Marc ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; COMPLEMENTARY DNA; CYCLIC AMP; RECEPTOR SUBTYPE; SYNTHETIC PEPTIDE; SYNTHETIC VASOACTIVE INTESTINAL POLYPEPTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING KINETICS; HORMONE RECEPTOR INTERACTION; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CLONING, MOLECULAR; COS CELLS; CYCLIC AMP; EXTRACELLULAR SPACE; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RADIOLIGAND ASSAY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0031933388     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adamou JJ, Aiyar N, VanHorn S and Elshourbagy NA (1995) Cloning and functional expression of the human intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:385-392.
2. Amiranoff B, Laburthe M and Rosselin G (1980) Characterization of specific binding sites for vasoactive intestinal peptide in rat intestinal epithelial cell membranes. Biochim Biophys Acta 627:215-224.
3. Baud V, Chissoe SL, Viegas-Pequignot E, Diriong S, N'Guyen VC, Roe BA and Lipinski M (1995) EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments. Genomics 6:334-344.
4. Bodanszky M, Bodanszky A, Klausner YS and Said SI (1974) A preferred conformation in the vasoactive intestinal peptide (VIP). Molecular architecture of gastrointestinal hormones. Bioorg Chem 3:1185-1193.
5. Bradford M (1979) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 78:248-254.
6. Couvineau A, Amiranoff B and Laburthe M (1986) Solubilization of the liver VIP receptor: Hydrodynamic characterization and evidence for an association with a functional GTP regulatory protein. J Biol Chem 261:14482-14489.
7. Couvineau A, Fabre C, Gaudin P, Maoret JJ and Laburthe M (1996a) Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 35:1745-1752.
8. Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P and Laburthe M (1995) Highly conserved aspartate 68, tryptophan 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem Biophys Res Commun 206:246-252.
9. Couvineau A, Rousset M and Laburthe M (1985) Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptor in the human colon adenocarcinoma cell line, HT-29. Biochem J 231:139-143.
10. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis, E and Laburthe M (1994) Human intestinal VIP receptors: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200:769-776.
11. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P and Laburthe M (1996b) Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 271:12795-12800.
12. Du K, Nicole P, Couvineau A and Laburthe M (1997) Aspartate 196 in the first extracellular loop of the human vasoactive intestinal peptide (VIP)1 receptor is involved in VIP binding. Biochem Biophys Res Commun 230:289-292.
13. Evan GI, Lewis GK, Ramsay G and Bishop JM (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogenes product. Mol Cell Biol 5:3610-3616.
14. Fong TM, Candelore MR and Strader CD (1995) Site-directed mutagenesis, in Receptor Molecular Biology (Sealfon SC ed) pp 263-277, Academic Press, San Diego.
15. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C and Laburthe M (1995) Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 211:901-908.
16. Hamman J, Eichler W, Hamman D, Kersten HMJ, Poddhige PJ, Hoovers JMN Hartmann E, Strauss M and Van Vlier RAW (1995) Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretin receptor superfamily with an unusual extracellular domain. J Immunol 155:1942-1950.
17. Hayes SA and Dice JF (1996) Roles of molecular chaperones in protein folding. J Cell Biol 132:255-258.
18. Holtmann MH, Hadac EM and Miller LJ (1995) Critical contributions of aminoterminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J Biol Chem 270:14394-14398.
19. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C and Nicole P (1996) Receptors for VIP, PACAP, secretin, glucagon, GLP-1 and other receptors of their new family of G protein-linked receptors: Structure-function relationship with special reference to the human VIP 1 receptor. Ann NY Acad Sci 805:94-109.
20. Laburthe M, Rousset M, Boissard C, Chevalier G, Zweibaum A and Rosselin G (1978) Vasoactive intestinal peptide (VIP): A potent stimulator of adenosine 3′,5′:cyclic monophosphate accumulation in gut carcinoma cell lines in culture. Proc Natl Acad Sci USA 75:2772-2775.
21. Laburthe M, Rousset M, Rouyer-Fessard C, Couvineau A, Chantret I, Chevalier G and Zweibaum A (1987) Development of vasoactive intestinal peptide-responsive adenylate cyclase during enterocytic differentiation of Caco-2 cells in culture. Evidence for an increased receptor level. J Biol Chem 262:10180-10184.
22. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G and Harmar AJ (1993) The VIP2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8.
23. Munson PJ and Rodbard D (1980) Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
24. Said SI and Mutt V (1970) Polypeptide with broad biological activity: Isolation from small intestine. Science (Wash DC) 169:1217-1218.
25. Segré GV and Goldring SR (1993) Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4:309-314.
26. Svoboda M, Tastenoy M, Van Rampelbergh J, Goosens JF, De Neef P, Waelbroeck M and Robberecht P (1994) Molecular cloning and functional characterization of a human receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 205: 1617-1624.
27. Usdin TB, Bonner TI and Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
28. Vilardaga JP, De Neef P, Di Paolo E, Bollen A, Waelbroeck M and Robberecht P (1995) Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem Biophys Res Commun 211:885-891.